New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
09:15 EDTGPK, TJX, ICPT, CAB, MRK, IRDM, NVS, CCL, ARX, ODP, DKS, ECYT, CLVS, OPHT, ACXM, URBN, SPLS, LIVE, DNDNOn The Fly: Pre-market Movers
HIGHER: Aeroflex (ARX), up 25% after agreeing to be acquired by Cobham for about $1.46B... Clovis (CLVS), up 6.6% after receiving breakthrough therapy designation for CO-1686... Ophthotech (OPHT), up 17.6% after entering into an ex-U.S. licensing, commercialization agreement with Novartis (NVS) for Fovista... Dendreon (DNDN), up 9% after announcing presentation of PROVENGE ProACT, IMPACT studies data... Iridium (IRDM), up 5% after upgraded at Raymond James... Acxiom (ACXM), up 3% after upgraded at Wells Fargo... Carnival (CCL), up 2% following upgrade at Morgan Stanley. DOWN AFTER EARNINGS: Dick's Sporting (DKS), down 15%. Peer Cabelas (CAB) also down 2% after Dick's report... Staples (SPLS), down 10%. Peer Office Depot (ODP) also down 2.6% after Staples' report... Urban Outfitters (URBN), down 4%... TJX (TJX), down 4.7%. ALSO LOWER: Intercept (ICPT), down 5.8% after The Street reported that the company knew of abnormal cholesterol levels in patients taking its liver disease drug obeticholic acid... Graphic Packaging (GPK), down 3% after offering 43.65M shares of common stock for holders... LiveDeal (LIVE), down 15% after entering 10M share common stock distribution agreement... Endocyte (ECYT), down 5% after company and partner Merck (MRK) withdraw CMA for vintafolide in Europe.... Molycorp (MCP), down 2.5% after downgraded at Morgan Stanley.
News For DKS;CAB;SPLS;ODP;ICPT;URBN;ARX;TJX;ACXM;CCL;GPK;OPHT;NVS;DNDN;CLVS;IRDM;LIVE;ECYT;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
December 8, 2014
16:24 EDTMRKAmgen initiates new combination trial for talimogene laherparepvec with KEYTRUDA
Subscribe for More Information
13:12 EDTMRKMerck paid full price but made good deal for Cubist, says UBS
Subscribe for More Information
13:07 EDTNVSNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
13:05 EDTNVSNovartis reports six-year results from Phase III ENESTnd study
Subscribe for More Information
12:40 EDTMRKOn The Fly: Midday Wrap
Subscribe for More Information
12:25 EDTMRKAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
11:30 EDTNVSLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
08:30 EDTMRKMerck says deals with Cubist includes $250M break-up fee clause
Subscribe for More Information
08:21 EDTMRKMerck says looked at all risks, including patent litgation, before Cubist deal
Subscribe for More Information
08:11 EDTMRKCubist volatility elevated into Merck acquiring for $8.4B in cash
Subscribe for More Information
08:08 EDTMRKMerck says about $9.5B of debt to be issued related to Cubist deal
Subscribe for More Information
07:35 EDTMRKAdvaxis reports FDA acceptance of IND application for ADXS-PSA combination trial
Subscribe for More Information
07:13 EDTMRKMerck to host conference call
Subscribe for More Information
07:01 EDTMRKMerck to acquire Cubist for $102 per share in cash, or $9.5B
Subscribe for More Information
07:00 EDTMRKMerck to acquire Cubist for $102 per share in cash
Subscribe for More Information
05:42 EDTNVSSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.
December 7, 2014
16:29 EDTMRKMerck in discussions to buy Cubist for $7B, Bloomberg reports
Subscribe for More Information
12:58 EDTMRKMerck presents KEYTRUDA data at ASH
Subscribe for More Information
December 5, 2014
09:42 EDTACXMDatalogix sale would be positive for Acxiom, says Stephens
Subscribe for More Information
06:06 EDTICPTIntercept announces publication of meta-analysis from Global PBC Study Group
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use